Docoh
Loading...

ABIO ARCA biopharma

News

From Benzinga Pro
5 Penny Stocks Insiders Are Buying
24 Nov 21
Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
ARCA biopharma Q3 EPS $(0.33), Same YoY
2 Nov 21
Earnings, News
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.33) per share. This is unchanged from the same period last year.
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 Nov 21
Pre-Market Outlook, Markets, Movers
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Oct 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
29 Oct 21
Biotech, Earnings, News, Guidance, Offerings, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
30 Stocks Moving in Friday's Pre-Market Session
29 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged
29 Oct 21
Biotech, Long Ideas, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19.
ARCA Biopharma Announces ASPEN-COVID-19 Data And Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial To Completion Based On Interim Analysis Of Efficacy And Safety Data
28 Oct 21
Biotech, News, General
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
ARCA Biopharma Announces Enrollment Of First International Patient In Phase 2b Clinical Trial Evaluating rNAPc2 As Potential Treatment For COVID-19
16 Sep 21
News, FDA
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first

Press releases

From Benzinga Pro
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
9 Nov 21
News, Press Releases
WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for
Investor Summit Group Provides Update on Upcoming Q4 Virtual Summit
8 Nov 21
Press Releases
New York, New York--(Newsfile Corp. - November 8, 2021) - The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the
Investor Summit Group Provides Update on Upcoming Q4 Virtual Summit
5 Nov 21
News, Press Releases
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
2 Nov 21
Earnings, Press Releases
On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with recommendation to continue
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
28 Oct 21
Health Care, Press Releases
Enrollment completion anticipated by year end 2021Topline data anticipated in first quarter of 2022 WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 Sep 21
Health Care, Press Releases, General
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in the fourth quarter